Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphoid 1Colorectal Neoplasms 1

Interventions

Imatinib Mesylate 18Dasatinib 12Cyclophosphamide 11fludarabine phosphate 9nilotinib 8fludarabine 7Sirolimus 6ruxolitinib 5Tacrolimus 5Mycophenolic Acid 5Cytarabine 5Azacitidine 5Whole-Body Irradiation 4Ipilimumab 4Busulfan 4Bortezomib 4thymoglobulin 3bosutinib 3belinostat 3aldesleukin 3Specimen Handling 3Nivolumab 3Interleukin-2 3Granulocyte Colony-Stimulating Factor 3Clofarabine 3CTLA-4 Antigen 3Antilymphocyte Serum 3AP 1903 reagent 3zileuton 2tozasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × tozasertib × Clear all
NCT00111683 2015-08-25

MK0457 in Patients With Leukemia (0457-003)

Merck Sharp & Dohme LLC

Phase 1 Completed
28 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00500006 2015-01-30

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡